Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.
Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.
Christopher W. Lievens, OD, MS, PhD, FAAO, FNAP, FBCLA, discusses his poster presentation titled "Latanoprostene bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension."
To kick off Perimenopause and Menopause Awareness Month, Meredith Bishop, OD, MS, FAAO, gives an overview of her poster "Perceptions of Linking Presbyopia with Perimenopause: A Survey of US Female Eye Care Professionals."
Michael Cymbor, OD, FAAO, gives an overview of a rapid fire lecture he gave in collaboration with Andrew Rixon OD, FAAO; Austin Lifferth, OD, FAAO; and Derek MacDonald, OD, FAAO, at AAOpt 2026.